{
    "info": {
        "nct_id": "NCT04761614",
        "official_title": "A Phase I Study of Riluzole in Combination With mFOLFOX6/Bevacizumab in Patients With Metastatic Colorectal Cancer",
        "inclusion_criteria": "* Patients with metastatic colorectal cancer, who are appropriate candidates to receive mFOLFOX6/bevacizumab. Patients who progressed on FOLFOX-based regimen are allowed\n* Willingness to undergo both pre-treatment and post-treatment tumor tissue biopsies (pre-treatment tumor tissue will be sent to pathology lab to confirm metastatic colorectal cancer as the standard of care)\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Age >= 18 years\n* Absolute neutrophil count >= (ANC) 1,500/ul\n* Platelets >= 100,000/ul\n* Hemoglobin >= 9 g/dl\n* Serum total bilirubin < 1.5 x ULN\n* Serum albumin >= 2.5 g/dl\n* If no liver involvement, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 x ULN. If liver involvement, AST and ALT =< 3.0 x ULN\n* Ability to understand and the willingness to sign a written informed consent document\n* A male subject of fathering potential must use an adequate method of contraception to avoid conception throughout the study (and for up to 12 weeks after the last dose of study drug) to minimize the risk of pregnancy. If the partner is pregnant or breastfeeding, the subject must use a condom\n* Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the last dose of study drug to minimize the risk of pregnancy. WOCBP must have a negative serum or urine pregnancy test within 72 hours before the start of the investigational product\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Patients who are receiving any other investigational agents\n* Patients with history of hepatitis B or C\n* Patients with severe renal impairment (CrCl < 30 mL/min)\n* Prior full field radiotherapy < 4 weeks or limited field radiotherapy < 2 weeks prior to first study drug administration. Patients with central nervous system (CNS) metastases may participate in this trial provided they are clinically stable. Patients who are < 1 month from radiation therapy must not be included\n* Patients with existing grade 2 peripheral neuropathy\n* Patients with a history of thrombotic or embolic events within the last six months such as a cerebrovascular accident (including transient ischemic attacks), pulmonary embolism or deep vein thrombosis\n* Cardiac conditions as follows:\n\n  * Active coronary artery disease, unstable or newly diagnosed angina or myocardial infarction less than 6 months prior to first study drug administration\n  * Class III-IV New York Heart Association (NYHA) congestive heart failure\n  * Uncontrolled hypertension (Systolic blood pressure [BP] > 150 mmHg and diastolic BP > 90 mmHg for 24 hours) despite optimal medical management\n  * Corrected QT (QTc) (Friderica) prolongation > 480 msec\n* Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, cardiac arrhythmia, active bleeding diatheses, and psychiatric illness/social situations that would limit compliance with study requirements\n* Major surgical procedure or significant traumatic injury less than 3 weeks or those who receive minor surgical procedures within 1 week from first dose of study drug administration\n* Known inability to swallow capsules\n* Inability to comply with study and/or follow-up procedures\n* Pregnant women are excluded from this study. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age >= 18 years",
            "criterions": [
                {
                    "exact_snippets": "Age >= 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum albumin >= 2.5 g/dl",
            "criterions": [
                {
                    "exact_snippets": "Serum albumin >= 2.5 g/dl",
                    "criterion": "serum albumin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2.5,
                                "unit": "g/dl"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A male subject of fathering potential must use an adequate method of contraception to avoid conception throughout the study (and for up to 12 weeks after the last dose of study drug) to minimize the risk of pregnancy. If the partner is pregnant or breastfeeding, the subject must use a condom",
            "criterions": [
                {
                    "exact_snippets": "A male subject of fathering potential",
                    "criterion": "male subject of fathering potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "male"
                        },
                        {
                            "requirement_type": "reproductive potential",
                            "expected_value": "fathering potential"
                        }
                    ]
                },
                {
                    "exact_snippets": "must use an adequate method of contraception to avoid conception throughout the study (and for up to 12 weeks after the last dose of study drug)",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "method adequacy",
                            "expected_value": "adequate"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "throughout the study",
                                "up to 12 weeks after the last dose of study drug"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "If the partner is pregnant or breastfeeding, the subject must use a condom",
                    "criterion": "condom use if partner is pregnant or breastfeeding",
                    "requirements": [
                        {
                            "requirement_type": "partner status",
                            "expected_value": [
                                "pregnant",
                                "breastfeeding"
                            ]
                        },
                        {
                            "requirement_type": "condom use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willingness to undergo both pre-treatment and post-treatment tumor tissue biopsies (pre-treatment tumor tissue will be sent to pathology lab to confirm metastatic colorectal cancer as the standard of care)",
            "criterions": [
                {
                    "exact_snippets": "Willingness to undergo both pre-treatment and post-treatment tumor tissue biopsies",
                    "criterion": "willingness to undergo tumor tissue biopsies",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "pre-treatment",
                                "post-treatment"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "pre-treatment tumor tissue will be sent to pathology lab to confirm metastatic colorectal cancer",
                    "criterion": "metastatic colorectal cancer diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation via pathology",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count >= (ANC) 1,500/ul",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count >= (ANC) 1,500/ul",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "/ul"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum total bilirubin < 1.5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Serum total bilirubin < 1.5 x ULN",
                    "criterion": "serum total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to understand and the willingness to sign a written informed consent document",
            "criterions": [
                {
                    "exact_snippets": "Ability to understand",
                    "criterion": "cognitive ability",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to sign a written informed consent document",
                    "criterion": "willingness to provide informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If no liver involvement, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 x ULN. If liver involvement, AST and ALT =< 3.0 x ULN",
            "criterions": [
                {
                    "exact_snippets": "If no liver involvement, aspartate aminotransferase (AST) ... =< 1.5 x ULN",
                    "criterion": "aspartate aminotransferase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "liver involvement",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "If no liver involvement, ... alanine aminotransferase (ALT) =< 1.5 x ULN",
                    "criterion": "alanine aminotransferase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "liver involvement",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "If liver involvement, AST ... =< 3.0 x ULN",
                    "criterion": "aspartate aminotransferase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "liver involvement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "If liver involvement, ... ALT =< 3.0 x ULN",
                    "criterion": "alanine aminotransferase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "liver involvement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the last dose of study drug to minimize the risk of pregnancy. WOCBP must have a negative serum or urine pregnancy test within 72 hours before the start of the investigational product",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the last dose of study drug",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": "adequate method"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "throughout the study and for up to 12 weeks after the last dose of study drug"
                        }
                    ]
                },
                {
                    "exact_snippets": "WOCBP must have a negative serum or urine pregnancy test within 72 hours before the start of the investigational product",
                    "criterion": "pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "test type",
                            "expected_value": [
                                "serum",
                                "urine"
                            ]
                        },
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 72 hours before the start of the investigational product"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets >= 100,000/ul",
            "criterions": [
                {
                    "exact_snippets": "Platelets >= 100,000/ul",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "/ul"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with metastatic colorectal cancer, who are appropriate candidates to receive mFOLFOX6/bevacizumab. Patients who progressed on FOLFOX-based regimen are allowed",
            "criterions": [
                {
                    "exact_snippets": "Patients with metastatic colorectal cancer",
                    "criterion": "colorectal cancer",
                    "requirements": [
                        {
                            "requirement_type": "metastatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "appropriate candidates to receive mFOLFOX6/bevacizumab",
                    "criterion": "appropriateness for mFOLFOX6/bevacizumab",
                    "requirements": [
                        {
                            "requirement_type": "candidate suitability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who progressed on FOLFOX-based regimen are allowed",
                    "criterion": "progression on FOLFOX-based regimen",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin >= 9 g/dl",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin >= 9 g/dl",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dl"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status 0-1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0-1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, cardiac arrhythmia, active bleeding diatheses, and psychiatric illness/social situations that would limit compliance with study requirements",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled concurrent illness ... ongoing or active infection",
                    "criterion": "ongoing or active infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Uncontrolled concurrent illness ... cardiac arrhythmia",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Uncontrolled concurrent illness ... active bleeding diatheses",
                    "criterion": "active bleeding diatheses",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric illness/social situations that would limit compliance with study requirements",
                    "criterion": "psychiatric illness/social situations limiting compliance",
                    "requirements": [
                        {
                            "requirement_type": "impact on compliance",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgical procedure or significant traumatic injury less than 3 weeks or those who receive minor surgical procedures within 1 week from first dose of study drug administration",
            "criterions": [
                {
                    "exact_snippets": "Major surgical procedure ... less than 3 weeks ... from first dose of study drug administration",
                    "criterion": "major surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "significant traumatic injury less than 3 weeks ... from first dose of study drug administration",
                    "criterion": "significant traumatic injury",
                    "requirements": [
                        {
                            "requirement_type": "time since injury",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "minor surgical procedures within 1 week from first dose of study drug administration",
                    "criterion": "minor surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Corrected QT (QTc) (Friderica) prolongation > 480 msec",
            "criterions": [
                {
                    "exact_snippets": "Corrected QT (QTc) (Friderica) prolongation > 480 msec",
                    "criterion": "QTc interval (Friderica)",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 480,
                                "unit": "msec"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with a history of thrombotic or embolic events within the last six months such as a cerebrovascular accident (including transient ischemic attacks), pulmonary embolism or deep vein thrombosis",
            "criterions": [
                {
                    "exact_snippets": "history of thrombotic or embolic events within the last six months",
                    "criterion": "thrombotic or embolic events",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "cerebrovascular accident (including transient ischemic attacks)",
                    "criterion": "cerebrovascular accident or transient ischemic attack",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "pulmonary embolism",
                    "criterion": "pulmonary embolism",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "deep vein thrombosis",
                    "criterion": "deep vein thrombosis",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Class III-IV New York Heart Association (NYHA) congestive heart failure",
            "criterions": [
                {
                    "exact_snippets": "Class III-IV New York Heart Association (NYHA) congestive heart failure",
                    "criterion": "congestive heart failure (NYHA)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "Class III",
                                "Class IV"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known inability to swallow capsules",
            "criterions": [
                {
                    "exact_snippets": "Known inability to swallow capsules",
                    "criterion": "ability to swallow capsules",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant women are excluded from this study. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued",
            "criterions": [
                {
                    "exact_snippets": "Pregnant women are excluded from this study",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding should be discontinued",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inability to comply with study and/or follow-up procedures",
            "criterions": [
                {
                    "exact_snippets": "Inability to comply with study and/or follow-up procedures",
                    "criterion": "ability to comply with study and follow-up procedures",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior full field radiotherapy < 4 weeks or limited field radiotherapy < 2 weeks prior to first study drug administration. Patients with central nervous system (CNS) metastases may participate in this trial provided they are clinically stable. Patients who are < 1 month from radiation therapy must not be included",
            "criterions": [
                {
                    "exact_snippets": "Prior full field radiotherapy < 4 weeks ... prior to first study drug administration",
                    "criterion": "prior full field radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "limited field radiotherapy < 2 weeks prior to first study drug administration",
                    "criterion": "prior limited field radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with central nervous system (CNS) metastases may participate in this trial provided they are clinically stable",
                    "criterion": "central nervous system (CNS) metastases",
                    "requirements": [
                        {
                            "requirement_type": "clinical stability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who are < 1 month from radiation therapy must not be included",
                    "criterion": "time since any radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active coronary artery disease, unstable or newly diagnosed angina or myocardial infarction less than 6 months prior to first study drug administration",
            "criterions": [
                {
                    "exact_snippets": "Active coronary artery disease",
                    "criterion": "coronary artery disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable or newly diagnosed angina",
                    "criterion": "angina",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        },
                        {
                            "requirement_type": "diagnosis_time",
                            "expected_value": "newly diagnosed"
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction less than 6 months prior to first study drug administration",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "time_since_event",
                            "expected_value": {
                                "operator": "<",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled hypertension (Systolic blood pressure [BP] > 150 mmHg and diastolic BP > 90 mmHg for 24 hours) despite optimal medical management",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled hypertension (Systolic blood pressure [BP] > 150 mmHg and diastolic BP > 90 mmHg for 24 hours)",
                    "criterion": "blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "systolic BP",
                            "expected_value": {
                                "operator": ">",
                                "value": 150,
                                "unit": "mmHg"
                            }
                        },
                        {
                            "requirement_type": "diastolic BP",
                            "expected_value": {
                                "operator": ">",
                                "value": 90,
                                "unit": "mmHg"
                            }
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 24,
                                "unit": "hours"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "despite optimal medical management",
                    "criterion": "medical management of hypertension",
                    "requirements": [
                        {
                            "requirement_type": "optimal management",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cardiac conditions as follows:",
            "criterions": [
                {
                    "exact_snippets": "Cardiac conditions",
                    "criterion": "cardiac conditions",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with severe renal impairment (CrCl < 30 mL/min)",
            "criterions": [
                {
                    "exact_snippets": "severe renal impairment (CrCl < 30 mL/min)",
                    "criterion": "renal impairment",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "CrCl < 30 mL/min",
                    "criterion": "creatinine clearance (CrCl)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who are receiving any other investigational agents",
            "criterions": [
                {
                    "exact_snippets": "Patients who are receiving any other investigational agents",
                    "criterion": "receipt of investigational agents",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with existing grade 2 peripheral neuropathy",
            "criterions": [
                {
                    "exact_snippets": "existing grade 2 peripheral neuropathy",
                    "criterion": "peripheral neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "grade 2"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Patients with history of hepatitis B or C",
            "criterions": [
                {
                    "exact_snippets": "history of hepatitis B",
                    "criterion": "hepatitis B",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of hepatitis C",
                    "criterion": "hepatitis C",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}